Eli Lilly stock slips after Novo Nordisk trims 2025 forecast; Jaypirca meets endpoint in CLL trial against J&J's Imbruvica, ...

Merck stock slid Tuesday after the company’s earnings failed to ease growing worries about the impending expiration of the ...

UnitedHealth shares continue to struggle after the company issued a fresh outlook for 2025, indicating revenue and adjusted ...

Today, we are on the lookout for more than 170 reports per Nasdaq. Many of them happened this morning. Here were the top 10 reports (by market cap) happening in the A.M. Here are some of the ...

Therini Bio, Inc., a clinical-stage biotech company developing fibrin-targeting immunotherapies for neurodegenerative diseases driven by vascular dysfunction today announced that the first patient has ...

Eli Lilly (LLY) stock in focus as its cancer drug Jaypirca hits main goal in a Phase 3 trial against Imbruvica of J&J (JNJ) ...

The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called ...

The program was formally launched July 28 at a signing ceremony at Wake Tech’s Beltline Education Center in Raleigh. Leaders ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...